Tumors with high levels of expression of TGFB2 and in combination with high levels of IFNGR2, IRF1, IRF5, CD86, CD68, MSR1/CD204, and CD276 exhibited negative prognosis for OS outcomes, providing for new modes of therapy for low-grade gliomas that are capable of knocking down TGFB2 expression in combination with either IRF5 blockade or targeting CD276/B7-H3. This evidence concerns the gene IRF5 and central nervous system cancer.